Evolution of eligibility criteria for diffuse large B‐cell lymphoma randomised controlled trials over 30 years
- 14 April 2021
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 193 (4) , 741-749
Abstract
Summary: Eligibility criteria for randomised control trials (RCT) in diffuse large B‐cell lymphoma (DLBCL) may be becoming increasingly strict. In this analysis, 42 first‐line phase III RCTs enrolling DLBCL patients since 1990 were identified from PubMed and clinicaltrials.gov. Changes in 31 individual eligibility criteria were assessed using three pre‐defined eras [(1) 1993–2005; (2) 2006–2013; and (3) 2014–2020]. The presence of 15/31 criteria increased significantly over time, and the total number of criteria per study also increased over time [median Era 1: 14·5, interquartile range (IQR) 12·6–16·4; Era 2: 21, 18·8–23·3; Era 3: 23, 21–25; P < 0·001]. When each trial's eligibility criteria were applied to 215 consecutive patients from an institutional database treated between 2010 and 2020, a median of 57% (IQR 47–70) of patients were hypothetically eligible for trial enrolment. The median percentage of patients eligible was 68% (56–91), 54% (37–81) and 47% (38–82) for Era 1, 2 and 3 respectively (P = 0·004). Phase III front‐line DLBCL trial criteria have become increasingly restrictive over the last three decades, resulting in a diminishing proportion of trial‐eligible patients, with less than 50% of our patients eligible for modern‐era studies. This potentially impacts generalisability of recent trial results and will likely limit recruitment to ongoing studies.Keywords
This publication has 16 references indexed in Scilit:
- Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2017
- The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignanciesLeukemia, 2016
- Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell LymphomasJournal of Clinical Oncology, 2016
- Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapiesCancer Treatment Reviews, 2015
- Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trialHaematologica, 2015
- R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomesHaematologica, 2014
- Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cyclesThe Lancet, 2013
- Patient Income Level and Cancer Clinical Trial ParticipationJournal of Clinical Oncology, 2013
- Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2006
- Participation in Cancer Clinical TrialsJAMA, 2004